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Prospective telehealth analysis of functional
performance, frailty, quality of life, and mental
health after COVID-19 hospitalization
Jacob J. Capin1,2,3, Melissa P. Wilson4, Kristine Hare1, Swati Vempati5, Carley E. Little6, Donna McGregor5,
Jose Castillo‑Mancilla5, Jennifer E. Stevens‑Lapsley1,3, Sarah E. Jolley7 and Kristine M. Erlandson5*

Abstract
Background: COVID-19 is a global pandemic with poorly understood long-term consequences. Determining the
trajectory of recovery following COVID-19 hospitalization is critical for prioritizing care, allocating resources, facilitating
prognosis, and informing rehabilitation. The purpose of this study was to prospectively evaluate recovery following
COVID-19 hospitalization.
Methods: Participants age 18 years or older who were hospitalized for ≥24 h due to COVID-19 completed phone/
video call virtual assessments (including the 10-time chair rise test) and survey forms at three time points (2–6, 12,
and 18 weeks) after hospital discharge. Univariate logistic and linear regression models assessed the associations of
the outcomes with primary predictors (categorical age, sex, race/ethnicity group, and categorical pre-hospitalization
frailty) at baseline; the same were used to assess differences in change from week 2–6 (continuous outcomes) or
outcome persistence/worsening (categorical) at last contact.
Results: One hundred nine adults (age 53.0 [standard deviation 13.1]; 53% female) participated including 43 (39%)
age 60 or greater; 59% identified as an ethnic and/or racial minority. Over 18 weeks, the mean time to complete the
10-time chair rise test decreased (i.e., improved) by 6.0 s (95% CI: 4.1, 7.9 s; p < 0.001); this change did not differ by
pre-hospital frailty, race/ethnicity group, or sex, but those age ≥ 60 had greater improvement. At weeks 2–6, 67% of
participants reported a worse Clinical Frailty Scale category compared to their pre-hospitalization level, whereas 42%
reported a worse frailty score at 18 weeks. Participants who did not return to pre-hospitalization levels were more
likely to be female, younger, and report a pre-hospitalization category of ‘very fit’ or ‘well’.
Conclusions: We found that functional performance improved from weeks 2–6 to 18 weeks of follow-up; that
incident clinical frailty developed in some individuals following COVID-19; and that age, sex, race/ethnicity, and prehospitalization frailty status may impact recovery from COVID-19. Notably, individuals age 60 and older were more
likely than those under age 45 years to return to their pre-hospitalization status and to make greater improvements
in functional performance. The results of the present study provide insight into the trajectory of recovery among a
representative cohort of individuals hospitalized due to COVID-19.
Keywords: COVID19, Frailty, Function, Quality of life, Posttraumatic stress disorder, Recovery
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Background
Coronavirus disease (COVID)-19 is a global pandemic
with poorly understood long-term consequences. Recent
data suggest that even mild cases of COVID-19 can result
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in significant long-term morbidity [1]. Determining the
trajectory of recovery in patients following COVID-19
hospitalization is critical for prioritizing care, allocating resources, facilitating prognosis, and informing
rehabilitation.
Post-acute sequelae of COVID-19 (PASC), often
defined as symptoms persisting at least 4 weeks beyond
initial symptom onset, may affect many organ systems
including pulmonary, hematologic, cardiovascular, neuropsychiatric, renal, endocrine, gastrointestinal, hepatobiliary, and dermatologic [2]. Sixty days after hospital
discharge, cardiopulmonary symptoms such as cough
and dyspnea, difficulty completing activities of daily living, inability to return fully to work, and emotional disturbances are among the most commonly reported
symptoms [3]. Six months after hospital discharge, the
most common symptoms reported by 1733 COVID-19
survivors from Wuhan, China were fatigue or muscle
weakness (63%), sleep difficulties (26%), and anxiety and/
or depression (23%); nearly one-quarter had 6-min walk
test (6-MWT) values below the lower limit of the normal range [4]. These studies suggest a high prevalence of
symptoms and functional limitations persist for weeks to
months in patients after COVID-19 hospitalization.
Although the aforementioned studies and others [2–8]
have begun to inform clinical practice and prognosis for
patients with post-acute sequelae of COVID-19 (PASC),
limitations to our understanding of the sequelae of
COVID-19 remain. Most studies to date are limited to
one cross-sectional evaluation [2–7], rather than longitudinal follow-up. Several studies have been performed
at post-COVID clinics [5, 7], in rehabilitation units [9],
or through social media outreach of COVID-19 support groups [10], which could bias towards individuals
with persistent or more severe symptoms. Another limitation of prior work is a dearth of performance-based
functional assessments, as many studies rely heavily or
exclusively on chart review and/or patient-reported outcomes [3, 6, 7]. Similarly, while many studies have identified frailty as a strong predictor of COVID-19 disease
severity and mortality [11–15], the effect of COVID-19
hospitalization on the development and/or progression
of clinical frailty is unknown. These limitations point to
a need for prospective, serial evaluation of outcomes,
including performance-based functional assessments, in
a representative sample of ‘all-comers’ following COVID19 hospitalization.
The purpose of this study was to prospectively evaluate and describe recovery in patients at multiple timepoints following a hospitalization due to COVID-19.
We hypothesized that: 1) outcomes would improve over
time (from 2 to 6 weeks post hospital discharge to 12 and
18 weeks post-discharge); 2) COVID-19 hospitalization
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would result in clinical frailty in some patients who did
not report pre-hospitalization frailty; and 3) age, sex,
race/ethnicity, and pre-hospitalization status would
impact recovery from COVID-19. These a priori hypotheses were guided by: 1) the natural course of recovery
experienced by most individuals following many acute
illnesses; 2) the prevalence of PASC and nosocomialrelated functional decline; and 3) prior studies identifying
associations between patient characteristics and outcomes following COVID-19 and other diseases.

Methods
Design

Prospective cohort study.
Ethics and consent to participate

All methods were carried out in accordance with the Declaration of Helsinki, and the study was approved by the
Colorado Multiple Institutional Review Board (COMIRB
20–0703 and COMIRB 20–0690). All participants provided electronic informed consent (via REDCap).
Setting and recruitment

Potential participants were identified using hospital discharge records at the University of Colorado Hospital
(Aurora, CO). Individuals were eligible to participate in
this study if they were at least 18 years of age and had
been hospitalized due to COVID-19 for more than 24 h
between March 2020 and November 2020 and subsequently discharged home (or prior place of residence);
participants requiring a higher level of care (e.g., skilled
nursing facility) were not included. Participants were
required to speak and read either English or Spanish, be
able to provide informed consent, and be able to access
online questionnaires through a computer, tablet, or
smart phone. While individuals could be enrolled in the
study up to 18 weeks following hospital discharge, most
were contacted and enrolled within the first 6 weeks.
Supplemental Fig. 1 provides a flow chart of screening
and enrollment.
Characteristics of participants

Characteristics of participants and of their hospitalizations were collected from medical record abstraction.
Data gleaned from the medical record included duration
of hospitalization, need for and duration of mechanical
ventilation, need for and duration of intensive care unit
(ICU) stay, comorbidities, discharge location, and need
for supplemental oxygen at discharge.
Virtual (video or phone) visits

Participants completed virtual research visits by video
(study preference) or telephone at 2–6 weeks, 12 weeks,
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and 18 weeks post-hospital discharge. Participants were
asked about changes in or lack of symptoms including
fever, shortness of breath, cough, dizziness, confusion,
fatigue, anosmia (i.e., loss of smell), and ageusia (i.e., loss
of taste).
Functional performance assessment (10‑time chair rise
test)

The 10-time chair rise test is a component of the
expanded Short Physical Performance Battery (SPPB), a
validated assessment of hospitalization, morbidity, and
mortality in middle-aged and older populations [16–18],
to capture function in higher-performing adults [19]. The
test is performed using a chair with no arms or padding
approximately 45 cm in height (i.e., a standard kitchen
table chair). For this study, testing was observed via video
or, to facilitate technological challenges and allow for telephone collection for those unable or unwilling to use
video, participants counted out loud as they stood from
the chair while on speaker phone. The same method
(video versus telephone) was used for each follow-up
assessment. Participants were first asked to rise from the
chair once. If the participant was unable to rise from the
chair or did not feel comfortable standing, the test was
stopped; otherwise, the person was subsequently asked
to rise 10 times as quickly as safely possible. Chair rise
time is responsive to change and predictive of outcomes
[20, 21].
Patient reported outcome measures

Participants completed patient reported outcome measures via online questionnaires on REDCap and/or telephone calls during the post-hospital assessment period.
All surveys were available in English and Spanish and
distributed to the participant in his or her preferred
language.
Clinical frailty scale

Participants estimated their function pre- and post-hospitalization using the Rockwood Clinical Frailty Scale
[22], an easy to interpret estimate of function than has
been recently applied extensively to participants with
COVID-19 [11–15, 23]. Participants estimated pre-hospitalization frailty level at their first post-discharge follow-up assessment (typically 2–6 weeks post-discharge),
and current frailty at each assessment. The scale consists
of nine ordinal responses ranging from (1) very fit to (9)
terminally ill. We categorized participants with scores
of 1 (very fit) and 2 (well) as non-frail and participants
with scores of 3 (managing well) or worse as pre-frail/
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frail. The Clinical Frailty Scale was administered online
via REDCap.
MRC dyspnea scale

The MRC Dyspnea Scale assesses perceived difficulty
breathing by answering yes or no to five statements from,
‘I only get breathless with strenuous exercise’ to ‘I am too
breathless to leave the house’ [24]. The MRC Dyspnea
Scale was administered during the phone/video call.
The World Health Organization disability assessment
schedule (WHODAS 2.0)

The World Health Organization Disability Assessment
Schedule 2.0 short form (WHODAS 2.0) measures disability due to health conditions including diseases, illness,
injuries, mental or emotional problems, and problems
with alcohol or drugs. The 12-item questionnaire covers six different adult life tasks including understanding
and communication, self-care, mobility, interpersonal
relationships, work and household activities, and community and civic roles. The sum score for global disability
ranges from 0 (no disability) to 48 (complete disability)
with higher scores representing greater (worse) disability. The WHODAS 2.0 has published normative data [25]
and was administered via REDCap.
Impact of event scale‑revised (IES‑6)

The Impact of Event Scale-Revised (IES-6) is an abbreviated six-item self-report measure that assesses subjective
distress caused by traumatic events [26] and has been
validated in survivors of acute respiratory distress syndrome [27]. Respondents indicate how much they were
distressed or bothered during the past seven days, as a
consequence of a recent event (i.e., hospitalization due to
COVID-19). The IES-6 was administered via REDCap.
Statistical analysis

Race and ethnicity information were combined to create four participant sub-groups: 1) White, non-Hispanic
(reference group); 2) Black, non-Hispanic; 3) Hispanic
(regardless of race); 4) and Other/Unknown. Due to small
sample size (n = 6), the “Other/Unknown” group was
excluded from modeling. Age was categorized into: 1)
age < 45 years (reference group), 2) age 45–59 years, and
3) age ≥ 60 years. Pre-hospitalization frailty was dichotomized as 1) non-frail and 2) pre-frail/frail according to
the previously described Clinical Frailty Score categories.
Linear regression (10-time chair rise test, WHODAS 2.0)
or logistic regression (categorical outcomes) models were
used to assess relationships between outcomes and primary predictors at baseline; the same were used to explore
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differences in improvement from week 2–6 (continuous
outcomes) or persistence/worsening of outcome measure
(categorical outcomes). Results were interpreted as significant in the context of the p-value (alpha = 0.05), estimate
(odds ratio [OR], or units specified), and 95% confidence
interval (CI). No adjustments were made for multiple
comparisons [28]. All graphic creation and data analysis
was performed using R statistical software (version 4.1.1).

Results
Participants and participant characteristics

One hundred nine individuals, including 43 (39%) age
60 and older, participated in the study (Table 1). Categorical age distribution differed by race/ethnicity group
(p = 0.001), with Hispanic participants tending to be
< 60 years of age. Detailed characteristics classified by participant age (Additional file 1: Appendix 1), sex (Additional
file 1: Appendix 2), and race/ethnicity groups (Additional
file 1: Appendix 3) may be found in the appendices. Longitudinal changes in post-hospital COVID-19 symptomatology at each assessed time point are shown in Fig. 1.
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Table 1 Demographic, social and medical characteristics
Demographics

N = 109

Mean age at admission (SD)

53.0 (13.1)

Male (%)

51 (46.8)

Race/Ethnicity (%)
Black/African-American, non-Hispanic

24 (22.0)

Hispanic, regardless of race

34 (31.2)

Other race, non-Hispanic

6 (5.5)

White, non-Hispanic

45 (41.3)

Education (%)
Some high school

5 (4.6)

High school graduate or GED

12 (11.0)

Some college or associate’s degree

23 (21.1)

Completed college or bachelor’s degree

14 (12.8)

Post-college (regardless of degree)

13 (11.9)

Missing

42 (38.5)

Alcohol consumption (%)
Yes

38 (34.9)

No

57 (52.3)

Unknown

14 (12.8)

Smoker (%)

Intensive care unit (ICU) admission

Yes

29 (26.6)

ICU admission occurred in 26% (28/109) of participants
and differed by categorical age (p = 0.02). Participants
age 60 and older were 76% less likely than participants
under 45 years to be admitted to the ICU (odds ratio
[OR]: 0.2 [95% CI: 0.1, 0.7], p = 0.010). Participants
age 45–59 years were 66% less likely than those under
45 years to be admitted to the ICU (OR: 0.3 [95% CI: 0.1,
1.0], p = 0.048). ICU admission status did not differ by
race/ethnicity, sex, or pre-hospitalization frailty category
in our sample of post-hospital participants (p > 0.3).

No

74 (67.9)

Unknown

6 (5.5)

Marijuana use (%)
Yes

8 (7.3)

No

62 (56.9)

Unknown

39 (35.8)

Substance abuse (%)

3 (2.8)

Comorbidities
Cardiovascular disease (%)

15 (13.8)

Respiratory disease (%)

27 (24.8)

Renal disease (%)

10 (9.2)

Assessment completion

Hypertension (%)

49 (45.0)

A total of 247 phone/video call assessments (symptoms,
10-time chair rise test, MRC Dyspnea) and 221 survey
forms (Clinical Frailty Scale, activity level, WHODAS
2.0, IES-6) were completed over the 3 time points (Additional file 1: Appendix 4). All 109 participants completed
at least one call and 78% (85/109) of participants completed surveys at one or more time point. Participants
who only participated at a single time point (n = 29) were
more likely to be younger (mean age: 48.5 vs 54.6 years;
p = 0.034), less likely to identify as non-Hispanic, White
(21% vs 49%; p = 0.016), and less likely to have completed
any survey (48% vs 89%; p < 0.001), as compared to participants who had data collected at multiple time points.

Type 2 diabetes (%)

37 (33.9)

Morbid obesity (%)

15 (13.8)

Functional performance

10‑time chair rise test At the week 2–6 visit, 72%
(73/101) of participants completed the 10-time chair rise

Hospital Course
Median days hospitalized [IQR]

4.0 [3.0, 9.0]

Admission to intensive care unit (ICU) (%)

28 (25.7)

Intubated (%)

14 (12.8)

Discharge location (%)
Home

98 (89.9)

Home with home health

4 (3.7)

Facility

4 (3.4)

Other

3 (2.8)

Discharged on oxygen (%)

56 (51.4)

test (Table 2). Those who could versus could not complete the exercise did not differ by sex, categorical age,
or race/ethnicity (Tables 3, 4, 5 and 6). Females took
longer than males (Table 3) and both African American
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Fig. 1 Participant-reported symptoms by survey week

and Hispanic participants took longer than non-Hispanic
White participants (Table 4) to complete the 10-time
chair rise test.
Among the 44 participants with 10-time chair rise test
at more than one time point, 89% (39/44) improved,
whereas 11% (5/44) had the same or worse time. On average, participants had a decrease (i.e., improvement) of
6.0 s (95% CI: 4.1, 7.9 s; p < 0.001). Those aged 60 or older
tended (p = 0.05) to improve more than those under age
45 years (Table 5).
Patient reported outcome measures

Clinical frailty scale Seventy participants reported prehospitalization frailty levels, with 66% (46/70) self-identifying as non-frail (i.e., ‘very fit’ or ‘well’). At weeks 2–6,
only 33% (21/64) of respondents had returned to their
pre-hospitalization frailty classification (Fig. 2; Table 2).
Post-hospitalization frailty (categorical) at weeks 2–6 did
not differ by sex, categorical age, or race/ethnicity.

Of the 46 participants who identified as non-frail prior to
their COVID-19-hospitalization, 83% (38/46) reported
Clinical Frailty Scale scores consistent with new prefrailty or frailty at one or more time point post-hospitalization. Of 59 participants who reported frailty information at week 18 (or week 12 if missing), 22% (13/59)
improved, 36% (21/59) were unchanged, and 42% (25/59)
reported worse frailty scores as compared to their
reported pre-hospitalization baseline. Participants who
did not return to their pre-hospitalization state were 3.4
times more likely to be female (Table 3), were more likely
to report being well or very-well prior to their hospitalization (Table 6), and tended to be younger (Table 5).
Secondary outcome measures

Secondary outcome measures (Table 2), including
the MRC Dyspnea Scale, WHODAS 2.0 (Fig. 3), and
IES-6, were reported and interpreted in the context
of the primary results. Females were 4.8 times more
likely than males to report continued use of oxygen
and report continued or new probable PTSD at final
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Table 2 Responses to primary and secondary outcomes measures at 2–6, 12, and 18 weeks post-discharge are provided
Interview Calls Completed
10-Time Chair Rise Testa
Mean [95% CI] seconds; N

Weeks 2–6

Week 12

Week 18

N = 101

N = 67

N = 63

29 [26, 32]; N = 73 25 [22, 28]; N = 50 21 [19, 23]; N = 43

Unable to complete due to physical ability or safety concerns, % (n/total)
Refused test (inconvenient), % (n/total)

16% (16/101)

12% (8/67)

11% (7/63)

12% (12/101)

13% (9/67)

21% (13/63)

MRC Dyspnea
38% (38/101)

64% (43/67)

71% (45/63)

Walking slower than most people or stopping on level ground due to dyspnea, % (n/
total)

Dyspnea only with strenuous exercise or when hurrying, % (n/total)

37% (37/101)

21% (14/67)

17% (11/63)

Dyspnea upon dressing and/or dyspnea that prevented them from leaving the house, %
(n/total)

26% (26/101)

15% (10/67)

11% (7/63)

40% (40/101)

27% (18/67)

29% (18/63)

Supplemental O2 Use
% (n/total)
Therapy
In-home care, % (n/total)

3% (3/101)

3% (2/67)

0% (0/63)

Outpatient PT and/or OT, % (n/total)

10% (10/101)

3% (2/67)

11% (7/63)

Survey Form (one or more section completed)
Reported Clinical Frailty Scale scorea

Weeks 2–6

Week 12

Week 18

N = 69

N = 56

N = 59

Pre-frail/frail score, % (n/total)

77% (51/66)

59% (33/56)

51% (30/59)

Return to pre-hospitalized level, % (n/total)

33% (21/64)

55% (27/49)

60% (29/48)

IES-6
Probable PTSD, % (n/total)

45% (31/69)

20% (11/56)

22% (13/59)

No PTSD, % (n/total)

55% (38/69)

80% (45/56)

78% (46/59)

WHODAS 2.0
Mean [95% CI]; N
Reported exercise
Return to pre-hospitalization level, % (n/total)
a

15 [12, 17]; N = 66 9 [6, 11]; N = 56

7 [5, 9]; N = 59

(Unavailable)b

69% (31/45)

63% (29/46)

b

Primary outcome; data collected at weeks 12 and 18 only

follow-up; odds ratios for other outcomes followed
these trends, albeit less strongly (Table 3). There were
no statistically significant differences in secondary
outcome measures according to racial/ethnic minority
group status (Table 4). Similar to the findings for the
10-time chair rise, participants aged 60 or older (compared to those under age 45) tended to be more likely
to improve on the MRC Dyspnea Scale, less likely to
report continued or new probable PTSD, and more
likely to return to their pre-hospitalization exercise
level (Table 5). Participants who were non-frail prehospitalization were less likely to return to their prehospitalization exercise level (Table 6).

Discussion
Among a diverse group of hospitalized individuals with COVID-19, we provide a detailed assessment of post-hospital recovery, incorporating both

functional performance and patient reported outcomes
over 18 weeks. As we hypothesized, 10-time chair rise
improved from 2-6 weeks to 18 weeks among the vast
majority (89%) of participants, with an average decrease
of 6.0 s, a robust and likely clinically meaningful change
consistent with the effects seen after 24 weeks of supervised exercise [29]. Next, 67% of participants reported
worse scores on the Clinical Frailty Scale 2–6 weeks postdischarge compared to their pre-hospitalization status.
Lastly, we found that age, sex, race/ethnicity, and prehospitalization status impacted recovery from COVID19, though with unique contributions to each outcome.
Notably, the study sample was relatively young (mean age
53 years) and limited to individuals discharged home (or
prior place of residence). Recovery may be slower among
older adults with greater frailty and comorbidities who
often experience more severe initial infections. Despite
these limitations to generalizability, the results of the
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Table 3 Differences in impairment among females compared to males, presented as estimate or odds ratio (OR) when indicated with
(95% confidence interval) and p-values for each outcome. Estimates that are statistically significant (p < 0.05) are bolded
Outcome; estimate type

Baseline difference
Est [95% CI] P-value

Week 18 d
 ifference*
Est [95% CI] P-value

10-Time Chair Rise Test
Unable to complete due to physical ability or safety concerns; OR
Time to complete; seconds
Change in time to complete from week 2/6; seconds

2.1 [0.7, 7.4]
P = 0.20

5.6 [0.2, 11.1]
P = 0.04

Clinical Frailty Scale
Post-hospitalization reported frailty; OR
Did not return to pre-hospitalization frailty; OR

0.8 [0.2, 2.5]
P = 0.67

MRC Dyspnea Scale
Too SOB to leave the house and/or SOB while dressing; OR
No improvement from week 2–6 answer; OR

2.0 [0.8, 5.3]
P = 0.13

IES-6
Met criteria for PTSD; OR
Continued or new PTSD; OR

1.3 [0.5, 3.5]
P = 0.53

WHODAS 2.0
Total score
Difference from week 2–6; score

4.4 [−0.3, 9.1]
P = 0.06

Supplemental O2
Reported use; OR
Continued or new use of supplemental O2; OR
Activity Level
Did not return to pre-hospitalization exercise; OR
*

2.0 [0.9, 4.5]
P = 0.10

0 [−3.2, 4.1]
P = 0.81

3.4 [1.2, 10.6]
P = 0.03

1.6 [0.6, 4.9]
P = 0.37

2.7 [0.9, 9.6]
P = 0.10

3.1 [−1.8, 8.1]
P = 0.21

4.8 [1.5, 19.0]
P = 0.01
1.2 [0.4, 3.8]
P = 0.8

Week 12 data used if week 18 data was unavailable

present study provide insight into the trajectory of recovery among an observational cohort of individuals who
were hospitalized due to COVID-19 and may inform how
providers counsel patients and/or direct additional treatments or therapies.
A strength of the present study was evaluating the
10-time chair rise test [19], an objective evaluation of
functional performance that is responsive to change and
predictive of poor outcomes [20, 21]. Few prior studies have reported on how objectively quantified physical
performance changes after COVID-19 hospitalization.
The 6 min walk test (6-MWT) [30] is used most often,
however, it measures endurance rather than strength, is

limited by dyspnea, cannot be performed in many clinical
locations due to space constraints, and is not easily done
in a virtual setting. Huang and colleagues found that 23%
of participants 6 months after COVID-19 had 6-MWT
distance below the lower limit of the normal range [4].
Wu and colleagues reported significant improvements in
the 6-MWT distance from 3 months to 6 months after
COVID-19 in 83 participants post-hospitalization, with
further improvements continuing at 9 and 12 months
[31]. Arnold et al., reported conducting a 1-min chair
stand test in 110 COVID-19 survivors 8–12 weeks after
COVID-19 hospitalization, but results of their chair
stand test do not appear in their brief communication

Capin et al. BMC Geriatrics

(2022) 22:251

Page 8 of 14

Table 4 Differences in impairment for racial/ethnic minorities compared to White, non-Hispanic participants, presented as estimate
or odds ratio (OR) when indicated with (95% confidence interval) and p-values for each outcome. Estimates that are statistically
significant (p < 0.05) are bolded
Week 18 difference *
Est [95% CI] P-value

Outcome; estimate type

Baseline difference
Est [95% CI] P-value

Race/Ethnicity category

Black/African Hispanic, regardless of race Black/African American, NH Hispanic, regardless of race
American, NH

10-Time Chair Rise Test
Unable to complete due to physical
ability or safety concerns; OR
Time to complete; seconds
Change in time to complete from
week 2/6; seconds

1.2 [0.3, 4.2]
P = 0.81

7.7 [2.0, 13.5]
P = 0.01

0.3 [0, 1.2]
P = 0.13

6.0 [1.1, 11.0]
P = 0.02

Clinical Frailty Scale
Post-hospitalization reported frailty;
OR
Did not return to pre-hospitalization
frailty; OR

0.3 [0.1, 1.4]
P = 0.14

0.3 [0.1, 1.2]
P = 0.09

1.1 [0.4, 3.4]
P = 0.80

0.4 [0.1, 1.3]
P = 0.14

2.8 [0.8, 10.1]
P = 0.11

1.7 [0.5, 5.7]
P = 0.41

3.2 [−2.9, 9.3]
P = 0.30

−4.0 [−10.0, 2.1]
P = 0.20

1.0 [0.3, 2.9]
P = 0.99

1.5 [0.6, 3.8]
P = 0.42

MRC Dyspnea Scale
Too SOB to leave the house and/or
SOB while dressing; OR
No improvement from week 2–6
answer; OR
IES-6
Met criteria for PTSD; OR
Continued or new PTSD; OR
WHODAS 2.0
Total score
Difference from week 2–6; score
Supplemental O2
Reported use; OR
Continued or new use of supple‑
mental O2; OR
Activity Level
Did not return to pre-hospitalization
exercise; OR
a

3.0 [−2.2, 8.1]
P = 0.25

2.7 [−1.6, 7.0]
P = 0.22

0.6 [0.1, 2.2]
P = 0.41

1.1 [0.3, 4.7]
P = 0.87

2.9 [0.7, 12.0]
P = 0.14

3.4 [0.9, 13.2]
P = 0.07

3.0 [0.7, 12.3]
P = 0.13

2.4 [0.6, 9.7]
P = 0.21

−4.1 [−10.5, 2.3]
P = 0.20

−4.7 [− 11.5, 2.1]
P = 0.17

1.0 [0.2, 4.6]
P = 0.96

1.9 [0.5, 6.7]
P = 0.35

0.9 [0.2, 3.6]
P = 0.89

0.3 [0, 1.7]
P = 0.23

Week 12 data used if week 18 data was unavailable

article [5]. In the present study, 89% improved, and participants > 60 years of age tended to improve more than
those under age 45, even with adjustment for the weeks
2–6 10-time chair rise. This may reflect a healthier older
population that did not require a higher level of care at
hospital discharge or greater drop-out among younger
participants with full recovery, although the present
study may select for healthier older participants as it
required patients to survive their hospitalization and be
discharged home (or to their prior place of residence)

to be eligible for the study. Further investigation of how
age and other factors may impact long-term COVID-19
recovery may help inform rehabilitation needs and referrals in the future.
The impact of COVID-19 hospitalization on change
in frailty status at multiple time points is a second
notable finding of our study. While a variety of factors
have been implicated in morbidity and mortality [2, 32,
33], frailty may be an especially important predictor
of outcomes for individuals with COVID-19 [11–14]
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Table 5 Differences in impairment among participants by age category compared to participants < 45 years of age, presented
as estimate or odds ratio (OR) when indicated with (95% confidence interval) and p-values for each outcome. Estimates that are
statistically significant (p < 0.05) are bolded
Outcome; estimate type

Baseline difference
Est [95% CI] P-value

Week 18 d
 ifference*
Est [95% CI] P-value

Age category

45–59

60 or greater

45–59

60 or greater

1.5 [0.3, 11.3]
P = 0.68

3.4 [0.8, 23.7]
P = 0.14

−2.7 [−7.9, 2.6]
P = 0.31

−5.1 [−10.3, 0]
P = 0.05

0.3 [0.1, 1.3]
P = 0.11

0.3 [0.8, 1.1]
P = 0.09

0.7 [0.2, 3.2]
P = 0.65

0.3 [0.1, 1.2]
P = 0.09

0.3 [0.1, 1.2]
P = 0.10

0.3 [0.1, 1.0]
P = 0.05

0.2 [−6.8, 7.1]
P = 0.96

2.3 [−4.2, 8.8]
P = 0.47

1.7 [0.3, 13.3]
P = 0.58

2.8 [0.6, 20.0]
P = 0.24

0.3 [0.1, 1.7]
P = 0.19

0.3 [0.1, 1.1]
P = 0.07

10-Time Chair Rise Test
Unable to complete due to physical ability or safety concerns; OR
Time to complete; seconds
Change in time to complete from week 2/6; seconds

−2.3 [−9.5, 4.9]
P = 0.52

−3.3 [−10.4, 3.8]
P = 0.36

Clinical Frailty Scale
Post-hospitalization reported frailty; OR
Did not return to pre-hospitalization frailty; OR

3.2 [0.7, 18.0]
P = 0.15

2.5 [0.6, 9.9]
P = 0.18

0.6 [0.2, 2.5]
P = 0.48

2.4 [0.8, 8.5]
P = 0.14

1.5 [0.4, 5.8]
P = 0.51

1.6 [0.5, 5.4]
P = 0.43

−1.1 [−7.5, 5.2]
P = 0.72

3.4 [−2.4, 9.2]
P = 0.25

0.9 [0.3, 2.8]
P = 0.91

1.3 [0.5, 3.7]
P = 0.61

MRC Dyspnea Scale
Too SOB to leave the house and/or SOB while dressing; OR
No improvement from week 2–6 answer; OR
IES-6
Met criteria for PTSD; OR
Continued or new PTSD; OR
WHODAS 2.0
Total score
Difference from week 2–6; score
Supplemental O2
Reported use; OR
Continued or new use of supplemental O2; OR
Activity Level
Did not return to pre-hospitalization exercise; OR
*

Week 12 data used if week 18 data was unavailable

(and other diseases and conditions). Two large metaanalyses have identified baseline frailty as a predictor
of mortality from COVID-19 [11, 12]. A prospective
cohort study of participants with COVID-19 over age
60 identified frailty as a significant and strong predictor of disease severity even after adjusting for age, sex,
body mass index, and multiple laboratory values [13].
Two-thirds of participants aged 65 years and older who
have been hospitalized with COVID-19 are frail, with
higher prevalence of frailty in women compared to men
and in older participants compared to younger ones

[15]. We found that among those who completed the
pre-hospitalization assessment, 65% reported being
‘very fit’ or ‘well’ prior to hospitalization with COVID19. In contrast, just 21, 41, and 49% at our follow-up
timepoints (2–6, 12, and 18 weeks post-discharge,
respectively) reported being ‘very fit’ or ‘well’, and 67%
of respondents at week 2–6 selected a worse frailty
condition compared to their pre-hospitalization level.
Our findings suggest new onset of pre-frailty or frailty
occurs in a substantial percentage of individuals following COVID-19 hospitalization (82% of previously
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Table 6 Differences in impairment by pre-hospital pre-frail/frail compared to non-frail, presented as estimate (95% confidence
intervals) and p-values for each outcome. Estimates that are statistically significant (p < 0.05) are bolded
Outcome; estimate type

Baseline difference
Est [95% CI] P-value

Week 18 d
 ifference*
Est [95% CI] P-value

10-Time Chair Rise Test
Unable to complete due to physical ability or safety concerns; OR
Time to complete; seconds
Change in time to complete from week 2/6; seconds

1.5 [0.3, 6.4]
P = 0.58

−0.5 [−7.9, 7.0]
P = 0.90

Clinical Frailty Scale
Post-hospitalization reported frailty; OR
Did not return to pre-hospitalization frailty; OR

1.2 [0.4, 4.2]
P = 0.81

MRC Dyspnea Scale
Too SOB to leave the house and/or SOB while dressing; OR
No improvement from week 2–6 answer; OR

1.7 [0.5, 5.1]
P = 0.38

IES-6
Met criteria for PTSD; OR
Continued or new PTSD; OR

0.6 [0.2, 1.6]
P = 0.28

WHODAS 2.0
Total score
Difference from week 2–6; score

−0.5 [−5.4, 4.4]
P = 0.84

Supplemental O2
Reported use; OR
Continued or new use of supplemental O2; OR
Activity Level
Did not return to pre-hospitalization exercise; OR
*

1.6 [0.6, 4.5]
P = 0.56

1.5 [−4.1, 7.1]
P = 0.59

0.0 [0.0, 0.2]
P = 0.003

1.0 [0.3, 3.7]
P = 0.99

0.7 [0.1, 2.8]
P = 0.64

−2.2 [−7.8, 3.5]
P = 0.45

5.6 [1.4, 23.7]
P = 0.02
0.2 [0.0, 0.8]
P = 0.048

Week 12 data used if week 18 data was unavailable

non-frail participants) and fails to resolve in some by
18 weeks later (39% of previously non-frail). It is possible, however, that the Clinical Frailty Scale is more
sensitive to functional deterioration rather than small
improvements in function and that recovery to higher
functional performance is more difficult than recovering to lower levels. Ongoing frailty may have a major
impact on healthcare utilization and vulnerability to
subsequent infections or conditions; persons with
ongoing or worsening frailty may benefit from rehabilitation programs to improve return to pre-hospital state.
We found substantially lower quality of life, evaluated using the WHODAS 2.0, in our study participants

compared to normative data [25]. At 2–6 weeks after
discharge, the mean score on the WHODAS 2.0 was 15,
which is the 95th (worst) percentile score for healthy
individuals age 45–54 years (our study mean age was
53). While scores improved on average 6.8 points, our
mean scores at weeks 12 and 18 were still between
the 85th and 90th percentiles for individuals aged
45–54 years, suggesting a lingering impact of COVID19 hospitalization.
We also found that symptoms of probable PTSD were
present in many individuals after COVID-19, as has
been observed following intensive care unit hospitalization due to non-COVID-19 related causes [34]. Among

Capin et al. BMC Geriatrics

(2022) 22:251

Page 11 of 14

Fig. 2 Self-reported post-hospitalization frailty compared to pre-hospitalization frailty by time point. The reference line indicates agreement
between pre- and post- hospital assessment: points above the line indicate post-hospital assessment was better than pre-hospital assessment
whereas points below the line indicate post-hospital assessment was worse

Fig. 3 WHODAS 2.0 questionnaire results by individual question topic and survey week. Each box represents a question assessing difficulties
experienced in performing the noted activity in the previous 14 days due to health-related conditions
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the 85 individuals in the present study who completed
the IES at least once, 46% (including 50% [11/22] who
were admitted to the ICU versus 44% [28/63] who were
not) met the IES threshold for probable PTSD [27]. Similarly, nearly half of all participants (238/488, or 49%) in
the Michigan cohort study reported being emotionally
affected by their health 60 days after being discharged
from COVID-19 hospitalization [3]. In a purposive sample of 100 survivors of COVID-19 4–8 weeks after hospitalization, Halpin et al. found that 24% of participants in
the hospital ward and 47% of participants in the ICU had
PTSD symptoms, including 77% of females compared to
just 39% of males in the ICU [6].
We found several consistent characteristics associated
with lingering impairments following COVID-19 hospitalization. Participants who did not return to pre-hospitalization frailty levels were more likely to be female, were
more likely to have reported pre-hospitalization frailty
category of ‘very fit’ or ‘well’, and tended to be younger.
Similarly, participants who did not return to their prehospitalization exercise level tended to be younger and
have answered ‘very fit’ or ‘well’ on the pre-hospitalization frailty assessment. Interestingly, participants under
age 45 years were more likely to be admitted to the ICU
compared to participants aged 45–59 years and those
over age 60 years. Similar to our findings, Halpin et al.
reported the median age of participants admitted to
the ICU was younger (58.5 years) compared to those in
the hospital ward (70.5 years) [6]. Moreno-Perez found
that persistent anosmia-dysgeusia was associated with
younger age, although they identified no baseline clinical features (including age, sex, ICU admission, hospital/ICU length of stay, etc.) as independent predictors of
PASC [8]. It is possible that older participants, including
those with milder cases of COVID-19, were more likely
to be hospitalized and/or more likely to go to a skilled
nursing facility following hospitalization (thus excluded
from the present study because of difficulty with followup early after hospitalization). Interestingly, participants
who have higher pre-hospitalization fitness levels may
have more difficulty, or at least more perceived difficulty,
returning to those levels despite having better overall
outcomes. Our findings suggest that females, younger
participants, and those who are ‘very fit’ or ‘well’ prior to
hospitalization may be less likely to perceive recovery to
prior functional levels thus could be more likely to benefit
from rehabilitation services. Further research is needed.
Longitudinal assessments are another strength of our
study. While many studies are limited to one cross-sectional analysis, Wu and colleagues recently published
a study evaluating respiratory outcomes 3, 6, 9, and
12 months following COVID-19-related hospitalization
[31]. Dyspnea scores and exercise capacity improved over
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time in the majority of the 83 participants, but a subgroup of participants 12 months after COVID-19 hospitalization had persistent physiological and radiographic
changes. Moreno-Perez also reported on select symptoms
at multiple timepoints after COVID-19 hospitalization
(2–3 months and 4 months), finding a lower prevalence of
persistent dyspnea and cough at 4 months compared to
2–3 months after COVID-19 infection in 277 survivors [8].
There are limitations to consider when interpreting
the results of the study. As discussed above, missing data
was more common in younger participants and minorities, indicating our findings may not fully represent
COVID-19 survivors discharged from hospital; however,
we did have a strong minority representation, as 59% of
participants in the present study identified as an ethnic and/or racial minority. We also only included participants who could understand English and/or Spanish,
although most potential participants understood at least
one of these languages. Many eligible patients were not
included due to patient volume, a lack of valid contact
information, failure to return calls/emails, and individuals declining enrollment. While only 109 (10.6%) of 1031
patients whom we attempted to contact participated
in the study, the most common reasons for not enrolling in the study were not answering the phone or email
(n = 428), declining to participate (n = 208), and phone
or technology issues (n = 99). Only 80 (7.8%) individuals
were ineligible due to medical reasons. We believe the
sample accurately reflects the majority of patients hospitalized due to COVID-19 except for those in the frailest pre-hospitalization categories. Our chair rise tests
(and all assessments) were conducted virtually; while
we took measures to ensure accuracy (including having
the participant count aloud and use video when possible), this form of data collection has not been validated
though is described by The Gerontological Society of
America [35]. Performing the tests remotely, however,
likely allowed us to capture a greater proportion of participants, thus our findings may be more generalizable.
Finally, our self-assessed clinical frailty measure may not
correspond to a provider-assessed scale, thus could capture perceived changes that are important to patients.

Conclusion
The purpose of this study was to prospectively evaluate
and describe recovery in participants at multiple timepoints following COVID-19 hospitalization. We found
that although functional performance improved up to
18 weeks following hospitalization, functional impairments and frailty persisted in a subset of patients. Potential explanatory factors, including age, sex, race/ethnicity,
and pre-hospitalization frailty status, impacted recovery
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from COVID-19 on some variables but not others. The
results of the present study provide insight into the trajectory of recovery among an observational cohort of
individuals (mean age 53 years) who were hospitalized
due to COVID-19 and may inform how providers counsel
patients and/or direct additional treatments or therapies.
Abbreviations
PASC: Post-acute sequelae of COVID-19; ICU: Intensive Care Unit; PTSD: Posttraumatic stress disorder; SPPB: Short Physical Performance Battery; 6-MWT:
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